Navigation Links
Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem
Date:3/8/2012

ch treatment.

Pevion is developing a first-in-class therapeutic vaccine, PEV7, to address this public health issue. PEV7 has recently demonstrated safety and immunogenicity in healthy volunteers.

About PEV7 therapeutic Candida vaccine

PEV7 is a clinical-stage therapeutic vaccine being developed for the treatment of recurrent vulvovaginal candidiasis (RVVC), a moderate-to-severe disease affecting 7% of all adult women. To date, there is no appropriate treatment for RVVC available. PEV7 is based on a protein antigen, Sap2, a key virulence factor of vulvovaginal candidiasis that is presented on the surface of virosomes. Pevion exclusively in-licensed the Sap2 antigen from its academic partner, the Istituto Superiore di Sanità (ISS) in Rome, Italy.

The ongoing PEV7 Phase I study is designed to assess the safety and immunogenicity of the therapeutic vaccine candidate in healthy volunteers. Half of the subjects will receive intramuscular injections, while the other half will receive capsules, administered intravaginally. In total, the study will enroll 48 healthy women of childbearing age. Positive interim results have already been announced.

About Virosomes

Virosomes are a regulatory and market-approved vaccine technology that fulfills carrier and adjuvant functions in one. Essentially, virosomes represent reconstituted empty influenza virus envelopes, devoid of the genetic material of the source virus. As such, virosomes do not replicate and are therefore an ideal combination of carrier plus adjuvant for almost any given antigen, including peptide or protein-derived antigens. The technology enables the use of poorly immunogenic antigens and thereby provides access to new indications and markets. Two virosome-based vaccines (Epaxal® and Inflexal® V, marketed by Crucell Switzerland AG) are licensed in over 40 countries, and more than 70 million doses of these vaccines have been commercially dis
'/>"/>

SOURCE Pevion Biotech AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing
2. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
3. Pevion Grants CSL Option Right to its Therapeutic Candida Vaccine
4. Pevions Therapeutic Candida Vaccine Generates Functional B Cell Memory in all Vaccinees
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... SAN DIEGO , March 27, 2015 /PRNewswire/ ... informatics company, today announced new data showing that, ... Mantis TM technology provided highly equivalent interpretations ... cause disease, and did so in a fraction ... pave the way for more comprehensive genetic analysis ...
(Date:3/27/2015)... Mass. , March 27, 2015 ... platform for drug discovery and development services which ... for the pharmaceutical industry, announced financial results for ... Timothy C.  Tyson, Chairman of XRpro Sciences ... to successfully transition from development stage to commercial ...
(Date:3/27/2015)... DALLAS , March 27, 2015 ... Market by Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation ... ICE, X-ray)) & Indication (AF, VT, WPW) - Global ... Market is expected to reach around ~$4.73 Billion by ... forecast period 2014 to 2019. Browse ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
...  One thousand women in Europe ... identified as a result of the   Sectra OneScreen   ... the risk of painful fractures because inexpensive and effective treatment ... throughout Europe are using this service to screen for osteoporosis, ...
... 2012   ULURU Inc. (NYSE AMEX: ULU),announced today ... been issued by the Therapeutic Goods Administration approving the ... the approval in Australia, Kerry P. Gray, President and ... in the worldwide commercialization of Altrazeal®.  Strategically this is ...
Cached Medicine Technology:1,000th Woman Identified Using Sectra's Analysis Method - European Mammography Clinics Mark Milestone in the Struggle Against Osteoporosis 21,000th Woman Identified Using Sectra's Analysis Method - European Mammography Clinics Mark Milestone in the Struggle Against Osteoporosis 3ULURU Inc. Announces Approval to Market Altrazeal® in Australia 2ULURU Inc. Announces Approval to Market Altrazeal® in Australia 3
(Date:3/27/2015)... While deep learning was the topic of many ... , the CEO of one start-up spoke passionately about using ... well beyond the generally-agreed ceiling of 120 years. , Insilico ... of 12 companies recognized as the hottest GPU-powered startups in ... GTC Emerging Companies Summit have business models focused on ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and ... information on and analysis of the healthcare, regulatory and ... US in 2013 amounted to 316.1 million, having grown ... from 2008. The country’s increasingly elderly population and corresponding ... to boost the growth of the pharmaceutical market, which ...
(Date:3/27/2015)... Milpitas, CA (PRWEB) March 27, 2015 ... company, today announced it has launched the SM1120 MEMS ... catheter market. The microsensor profile at only 220um ... enabling maneuverability to reach challenging locations. With industry ... per hour, the SM1120 provides a broad operating pressure ...
(Date:3/27/2015)... When struck with the aftermath of a trucking ... begin. The latest eBook released by Dax Jones ... victims a clear and concise process for obtaining the ... injury claim is seen through to successful completion. , ... should be taken immediately following the trucking incident. From ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... 2010 Neuralstem, Inc. (NYSE Amex: CUR) announced ... rat brains affected by stroke and differentiated predominantly ... in some motor skill and strength measurements. The ... Stem Cells To Reverse Motor Deficits in Chronic ...
... Families from rural Mexico who receive health care from centralized ... percent less in out-of-pocket expenses and utilize preventive services more ... states, according to a study by researchers at the UCLA ... published in the September issue of the Journal of ...
... By Serena Gordon HealthDay Reporter , MONDAY, Sept. 13 ... rather than the hospital results in higher quality-of-life scores at the ... as well. , A study published online Sept. 13 in ... people who died in intensive care units (ICU) or other areas ...
... small, seemingly benign holes in a child,s heart may ... could be lurking out of sight. These are the ... at Nationwide Children,s Hospital and the Ohio State University ... form of congenital heart disease, ventricular septal defect. The ...
... CLEMENTE, Calif. (September 13, 2010) USGI Medical, ... updated multi-center results confirm durability of the company,s ... more in a variety of incisionless gastrointestinal (GI) ... of Surgery, Endolumenal) to repair dilated tissue after ...
... used to treat attention-deficit/hyperactivity disorder (ADHD) also provides ... that affect many childhood cancer survivors, according to ... Research Hospital investigators. Researchers reported that one ... survivors scored better on tests of sustained attention ...
Cached Medicine News:Health News:Neuralstem stem cells survive and differentiate into neurons in rats with stroke 2Health News:Centralized health care more cost-effective, offers better access to preventive services 2Health News:Centralized health care more cost-effective, offers better access to preventive services 3Health News:Dying at Home Often Easier on Cancer Patients, Caregivers 2Health News:Dying at Home Often Easier on Cancer Patients, Caregivers 3Health News:Study identifies underlying dysfunction of seemingly non-critical heart condition 2Health News:USGI medical tissue anchors show durability beyond 1 year 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 2Health News:Childhood cancer survivors show sustained benefit from common ADHD medication 3
... digital single plane C-arm angiography system is ... performance and an expansive range of diagnostic ... to ECG triggered. ... of the art dynamic Flat Detector technology, ...
... Meta-4 Computerized ENG utilizes a ... comprehensive nystagmus and ocular motor ... storage, data analysis and reanalysis ... data in the Meta-4 software ...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Medicine Products: